It was the 5th year that Chronix Biomedical has been present at ASCO Annual Meeting in Chicago
This was the busiest ASCO conference yet for Chronix Biomedical. Chronix booth was visited by clinical trial oncologists, international cancer research...
Chronix Biomedical reports positive interim pancreatic cancer data
Chronix Biomedical reports a positive interim analysis of its ongoing validation study of its Copy Number Instability (CNI)-based therapeutic monitoring test in pancreatic cancer. The study compares the accuracy of Chronix’s CNI-based test at predicting a clinical response, as early as after the first cycle of chemotherapy compared to CA19-9, a commonly used biomarker.
Chronix Biomedical presents positive data on prognostic test in head/neck cancer study data at ASCO
Study finds CNI score to be a stronger predictor of time to recurrence in head and neck cancer than current method based on lymph node invasion. The study enrolled 54 patients undergoing surgery for this cancer type and evaluated the Chronix test as a predictor of time to progression in comparison with the current method based on the degree of tumour invasion of lymph nodes (pN status).
Cell-free DNA for treatment monitoring and outcome predictor in head and neck cancer
Chronix Biomedical presents positive data on prognostic test in head/neck cancer study data at ASCO. Study finds CNI score to be a stronger predictor of time to recurrence in head and neck cancer than current method based on lymph node invasion.
Chronix Biomedical is pleased to be a sponsor of the PCRT annual meeting
Chronix Biomedical
Chronix looks forward to working with this team of international pancreatic cancer experts.
Chronix at the ASCO 2017 Annual Meeting
Chronix Biomedical
This is the third year that Chronix is presenting its study results at ASCO — this year’s results are from a blinded prospective study validating the use of a CNI Monitor blood test to predict the treatment outcome of patients undergoing immunotherapy.